S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:THRX

Theseus Pharmaceuticals (THRX) Stock Price, News & Analysis

$4.06
0.00 (0.00%)
(As of 02/14/2024)
Today's Range
$4.06
$4.06
50-Day Range
$3.99
$4.08
52-Week Range
$2.05
$12.37
Volume
N/A
Average Volume
592,167 shs
Market Capitalization
$179.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75
THRX stock logo

About Theseus Pharmaceuticals Stock (NASDAQ:THRX)

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

THRX Stock Price History

THRX Stock News Headlines

Theseus Pharmaceuticals Announces Closing of Tender Offer
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Theseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In Cash
Theseus Pharmaceuticals Inc THRX
See More Headlines
Receive THRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:THRX
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.75
High Stock Price Target
$9.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+66.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-50,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.36 per share

Miscellaneous

Free Float
23,575,000
Market Cap
$179.57 million
Optionable
Optionable
Beta
3.98
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

THRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Theseus Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theseus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" THRX shares.
View THRX analyst ratings
or view top-rated stocks.

What is Theseus Pharmaceuticals' stock price target for 2024?

4 equities research analysts have issued 12-month target prices for Theseus Pharmaceuticals' shares. Their THRX share price targets range from $4.00 to $9.00. On average, they anticipate the company's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 66.3% from the stock's current price.
View analysts price targets for THRX
or view top-rated stocks among Wall Street analysts.

How have THRX shares performed in 2024?

Theseus Pharmaceuticals' stock was trading at $4.05 at the beginning of 2024. Since then, THRX stock has increased by 0.2% and is now trading at $4.06.
View the best growth stocks for 2024 here
.

How were Theseus Pharmaceuticals' earnings last quarter?

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) issued its quarterly earnings data on Monday, November, 15th. The company reported ($5.16) EPS for the quarter, missing the consensus estimate of ($0.23) by $4.93.

When did Theseus Pharmaceuticals IPO?

Theseus Pharmaceuticals (THRX) raised $150 million in an initial public offering (IPO) on Thursday, October 7th 2021. The company issued 10,000,200 shares at a price of $14.00-$16.00 per share.

Who are Theseus Pharmaceuticals' major shareholders?

Theseus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (4.79%), BML Capital Management LLC (2.51%), BML Capital Management LLC (2.51%), Vanguard Group Inc. (1.80%), Vanguard Group Inc. (1.80%) and Highbridge Capital Management LLC (1.39%). Insiders that own company stock include Bradford D Dahms, Carl L Gordon, Foresite Capital Management V, and Timothy P Clackson.
View institutional ownership trends
.

How do I buy shares of Theseus Pharmaceuticals?

Shares of THRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:THRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners